Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo Controlled Randomized, 12-week, Dose-ranging, Double-blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C in Women With Overactive Bladder Including Urge Urinary Incontinence

NCT00564226 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00564226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00564226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo Controlled Randomized, 12-week, Dose-ranging, Double-blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C in Women With Overactive Bladder Including Urge Urinary Incontinence
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2007
Completion date
February 28, 2009
Enrollment
345 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder